Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YAZ flex · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Drug: YAZ flex (SH T00186D) | DRUG | Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral)) |
| YAZ (SH T00186D) | DRUG | YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral)) |
Inclusion Criteria: * Otherwise healthy female patients with moderate to severe primary dysmenorrhea * Prospective self-rated sum pain score of \>/= 8 during the 2 baseline cycles * Age between 18 and 40 years (inclusive) with smoking habits as follows: * between 18 and 30 years of age. daily ci...
YAZ flex is being developed for the treatment of primary dysmenorrhea, a condition characterized by painful menstrual cramps. It is an investigational small molecule therapy studied in adult women aged 18 years and older. The clinical program has focused specifically on this indication rather than broader gynecological conditions.
YAZ flex is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the clinical program evaluating the drug in primary dysmenorrhea. The company conducted the Phase 3 trial of YAZ flex in Germany and the United Kingdom.
YAZ flex is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication based on the available development data.
YAZ flex has been evaluated in one completed Phase 3 trial, NCT00569244, titled SH T00186 in the Treatment of Primary Dysmenorrhea. The trial enrolled 223 participants across Germany and the United Kingdom, was randomized, active-controlled, and restricted to female participants aged 18 years and older.
Yes, YAZ flex is also known as SH T00186D. These names refer to the same investigational drug developed by Bayer AG for primary dysmenorrhea. The Phase 3 trial NCT00569244 used the SH T00186 designation in its title, confirming the connection between the two names.